Review
Medicine, General & Internal
Mohammad Almohideb
Summary: Nivolumab shows good efficacy in melanoma patients with lower rates of adverse events. Nivolumab monotherapy and its combination with ipilimumab have different survival rates at different time points.
Review
Oncology
Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati
Summary: The Bayesian network meta-analysis of randomized controlled trials showed that adjuvant therapy with nivolumab for resected melanoma patients provides comparable efficacy and safety compared to other approved treatments. At certain time points, the risk of recurrence with nivolumab is even lower than with other treatments.
Review
Immunology
Yao Xu, Kamal Hezam, Manasik Gumah Ali, Yang Wang, Juan Zhang
Summary: The combination therapy of Nivolumab and Ipilimumab showed greater overall response rate and progression-free survival compared with Nivolumab monotherapy, but did not significantly affect overall survival. The combination of Nivolumab 1mg/kg plus Ipilimumab 3mg/kg demonstrated better efficacy but was associated with a higher incidence of adverse effects.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2021)
Review
Oncology
Chan Zhang, Yaoxian Xiang, Jing Wang, Dong Yan
Summary: This study compared the efficacy of different treatment regimens for advanced gastric cancer or gastroesophageal junction carcinoma. The results showed that antibody drug conjugates (ADC) may be the best option for advanced gastric cancer patients, especially for those with HER2 overexpression, intestinal histopathology, previous gastrectomy history, gastric origination cancer, ages over 65 and ECOG PS=0/1. Nivolumab may be the first treatment option for gastroesophageal junction carcinoma patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Andrea Boutros, Enrica Teresa Tanda, Elena Croce, Fabio Catalano, Marcello Ceppi, Marco Bruzzone, Federica Cecchi, Luca Arecco, Matteo Fraguglia, Paolo Pronzato, Carlo Genova, Lucia Del Mastro, Matteo Lambertini, Francesco Spagnolo
Summary: The anti-LAG3 plus anti-PD-1 combination therapy has been approved as a treatment option for advanced melanoma. This study conducted a systematic review and network meta-analysis comparing different first-line treatment options in terms of progression-free survival, overall response rate, and treatment-related adverse events. The results showed that relatlimab/nivolumab had similar efficacy to ipilimumab/nivolumab but with a better safety profile.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Medicine, General & Internal
Xiao-Dan Ren, Xue Fu, Yuan-Qun He, Chun-Yan Li, Meng Guo, Min Qiao
Summary: This study found that sofosbuvir-velpatasvir was highly effective in the treatment of HCV patients. The addition of ribavirin significantly improved SVR12 rates in genotype-3 patients, but not in genotype-1 and genotype-2 patients.
Review
Endocrinology & Metabolism
Dongmei Huang, Jinming Zhang, Xiangqian Zheng, Ming Gao
Summary: Lenvatinib has shown meaningful antitumor activity but limited clinical efficacy in the treatment of anaplastic thyroid carcinoma (ATC).
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Infectious Diseases
Khalid Eljaaly, Jessica K. Ortwine, Mohammed Shaikhomer, Thamer A. Almangour, Matteo Bassetti
Summary: This study evaluated the efficacy and safety of eravacycline for complicated intra-abdominal infections, finding similar clinical efficacy and mortality compared with carbapenems. However, eravacycline was associated with higher odds of total adverse events and nausea, but no significant differences were observed in vomiting, serious adverse events, or discontinuation due to adverse events.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Review
Gastroenterology & Hepatology
Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford
Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.
Review
Immunology
Zao Ji, Feifei Jiang
Summary: This study systematically evaluated the clinical efficacy and safety of sublingual immunotherapy for allergic rhinitis. The findings showed that sublingual immunotherapy has better efficacy and safety compared to traditional medicine.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Xiaoming Li, Xia Yang, Zong Ning
Summary: This study conducted a systematic evaluation of the efficacy and safety of COVID-19 inactivated vaccines. The results showed that two doses of inactivated COVID-19 vaccines effectively prevented SARS-CoV-2 infection and associated hospitalizations in individuals over 18 years of age. However, the vaccines also caused a certain number of adverse events, with injection site pain being the most common.
FRONTIERS IN MEDICINE
(2022)
Review
Immunology
Mosunmoluwa Oyenuga, Mohamed M. G. Mohamed, Sara Sartaj, Rushin Patel, Abayomi Oyenuga, Sandeep Sen
Summary: Compared to standard chemotherapy, the use of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers is associated with improved overall and progression-free survival, with similar rates of adverse effects and adverse effects leading to death. The improvement in survival was significant in patients with ≥ 1% PD-L1 expression.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2023)
Review
Oncology
Yin Yang, Lei Deng, Yufan Yang, Tao Zhang, Yuqi Wu, Luhua Wang, Nan Bi
Summary: This study systematically evaluated the efficacy and toxicity of the combination of brain radiotherapy and immune checkpoint inhibitors for non-small-cell lung cancer patients. The results showed that the brain radiotherapy+immune checkpoint inhibitors model had significantly better systemic efficacy than brain radiotherapy alone, with similar neurological adverse events. Concurrent radiotherapy+immune checkpoint inhibitors were identified as the optimal model, achieving the best efficacy without significantly increased adverse events.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
E. Toulemonde, S. Chevret, M. Battistella, E. M. Neidhardt, C. Nardin, F. Le Du, N. Meyer, M. Veron, L. Gambotti, A. Lamrani-Ghaouti, P. Jamme, C. Chaffaut, M. De Pontville, E. Saada-Bouzid, M. Beylot-Barry, C. Simon, T. Jouary, A. Marabelle, L. Mortier
Summary: Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor. There is currently no consensus on the treatment of this cancer. A study evaluated the efficacy of Nivolumab in patients with Trichoblastic carcinoma, and found that it showed promising results with a good control of the disease. Further studies are needed to confirm these findings and determine the role of Nivolumab in the treatment of Trichoblastic carcinoma.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Medicine, General & Internal
Faping Wang, Xiaoju Tang, Min Zhu, Hui Mao, Huajing Wan, Fengming Luo
Summary: JAKinibs are effective in improving symptoms of RA patients compared to placebo, but are associated with more adverse events. Baricitinib and upadacitinib have a higher risk of adverse events and infections, while only baricitinib is associated with a higher risk of herpes zoster.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Tianjin Yi, Yi Feng, Ravi Sundaram, Yan Tie, Heng Zheng, Yanping Qian, Di You, Tao Yi, Ping Wang, Xia Zhao
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Medicine, General & Internal
Heng Zheng, Yan Tie, Xi Wang, Yang Yang, Xiawei Wei, Xia Zhao
Review
Chemistry, Medicinal
Yan Tie, Hui Yang, Rui Zhao, Heng Zheng, Daoke Yang, Jingyi Zhao, Ming Liu
DRUG DESIGN DEVELOPMENT AND THERAPY
(2019)
Review
Oncology
Fan Tang, Yan Tie, Weiqi Hong, Yuquan Wei, Chongqi Tu, Xiawei Wei
Summary: Surgical resection is a common treatment for primary solid tumors, but high rates of cancer recurrence and metastasis post-surgery contribute to cancer-related mortality. MDSCs play a crucial role in the formation of premetastatic niches and become more immunosuppressive after surgery, suggesting surgery enhances their function. Various therapies targeting MDSCs and associated inflammatory signals may improve long-term survival post-resection.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Fan Tang, Yan Tie, Xiawei Wei, Chongqi Tu
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Fan Tang, Yan Tie, Wei-Qi Hong, Xin He, Li Min, Yong Zhou, Yi Luo, Si-Yuan Chen, Jing-Yun Yang, Hou-Hui Shi, Xia-Wei Wei, Chong-Qi Tu
Summary: This study aims to establish a favorable preclinical translational platform for validating efficient and personalized therapeutic candidates for TGCT. The use of patient-derived tumor xenograft (PDTX) mouse models in nude mice and ex vivo cultures of patient-derived explants (PDEs) were shown to be effective in evaluating response patterns to CSF1R inhibitors.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Fan Tang, Yan Tie, Yu-Quan Wei, Chong-Qi Tu, Xia-Wei Wei
Summary: Sarcomas are a rare and heterogeneous group of malignant tumors with limited treatment options, but targeted therapy and immunotherapy show promising potential. Among the drugs, anti-angiogenesis therapy has shown favorable efficacy in sarcomas.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Review
Oncology
Fan Tang, Yan Tie, Chongqi Tu, Xiawei Wei
CLINICAL AND TRANSLATIONAL MEDICINE
(2020)
Article
Medicine, Research & Experimental
Xia Yuan, Wen Nie, Zhiyao He, Jingyun Yang, Bin Shao, Xuelei Ma, Xiangxian Zhang, Zhenfei Bi, Lu Sun, Xiao Liang, Yan Tie, Yu Liu, Fei Mo, Dan Xie, Yuquan Wei, Xiawei Wei
Article
Biochemistry & Molecular Biology
Tie Yan, Zheng Heng, He Zhiyao, Yang Jingyun, Shao Bin, Liu Li, Luo Min, Yuan Xia, Liu Yu, Zhang Xiangxian, Li Hongyi, Wu Min, Wei Xiawei
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2020)
Article
Biochemistry & Molecular Biology
Heng Zheng, Yan Tie, Zhen Fang, Xiaoai Wu, Tao Yi, Shuang Huang, Xiao Liang, Yanping Qian, Xi Wang, Ruyu Pi, Siyuan Chen, Yong Peng, Shengyong Yang, Xia Zhao, Xiawei Wei
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2019)
Article
Oncology
Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa
Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.
INTERNATIONAL JOURNAL OF CANCER
(2024)
Correction
Oncology
J. Gu, S. Xie, S. Wang
INTERNATIONAL JOURNAL OF CANCER
(2024)